ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

  • STATUS
    Not Recruiting
  • sponsor
    Bayer
Updated on 8 August 2022
measurable disease
pembrolizumab
EGFR

Summary

This clinical study aims to investigate if impairment of the deoxyribonucleic acid damage repair (DDR) pathway by the Elimusertib in combination with blockade of the PD-1/PD-L1 pathway by pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk ratio.

Description


Details
Condition Gastric Cancer, solid tumors, Pancreatic cancer, CRPC, nsclc, solid tumor, mCRPC, Pancreatic Cancer, Prostate Cancer, Lung cancer, Islet Ce417ll Cancer, oncology, NSCLC, Prostate cancer, ATR, Stomach Cancer, GI cancer
Clinical Study IdentifierTX279019
SponsorBayer
Last Modified on8 August 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note